BMRN
Biomarin Pharmaceutical Inc
$60.35
+1.56 (+2.65%)
At close · Jul 7
Market Cap
$11.66B
Shares
193,284,438
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.22B
+12.9%
FY2025
Net Income
$348.9M
-18.3%
FY2025
Gross Margin
77.73%
-1.9pp
FY2025
Operating Margin
12.71%
-4.3pp
FY2025
Diluted EPS
$1.80
-18.6%
FY2025
Operating Cash Flow
$827.99M
+44.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.83B – $3.93B | $3.24B | $3.22B | $2.85B | $2.42B | $2.1B | $1.85B | $1.86B | $1.7B | $1.49B | $1.31B | $1.12B | $889.9M | $749.28M | $548.49M | $500.72M | $441.36M | $376.27M | $324.66M | $296.49M | |
| — | $760.88M | $717.44M | $580.24M | $532.06M | $503.02M | $470.52M | $524.27M | $359.47M | $315.26M | $241.79M | $209.62M | $152.01M | $122.27M | $88.39M | $91.83M | $84.02M | $70.29M | $65.91M | $52.51M | |
| — | $2.48B | $2.5B | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B | $1.34B | $1.18B | $1.07B | $907.23M | $737.89M | $627.02M | $460.09M | $408.89M | $357.34M | $305.98M | $258.75M | $243.98M | |
| — | — | 77.73% | 79.67% | 78.01% | 76% | 74.52% | 71.82% | 78.91% | 78.86% | 81.59% | 81.23% | 82.92% | 83.68% | 83.88% | 81.66% | 80.96% | 81.32% | 79.7% | 82.29% | |
| — | $942M | $921.93M | $747.18M | $746.77M | $649.61M | $628.79M | $628.12M | $715.01M | $696.33M | $610.75M | $661.91M | $634.81M | $461.54M | $354.78M | $302.22M | $214.37M | $147.31M | $115.12M | $93.29M | |
| — | $1.21B | $1.15B | $1.01B | $892.41M | $823.24M | $759.38M | $737.67M | $680.92M | $604.35M | $554.34M | $476.59M | $402.27M | $302.16M | $235.36M | $198.17M | $175.42M | $151.72M | $124.29M | $106.57M | |
| — | $19.02M | $19.39M | $43.26M | $62.21M | $67.19M | — | — | — | — | — | — | — | $10.49M | — | $6.8M | $500K | — | — | — | |
| — | — | $79.56M | $96.43M | $104.39M | $101.97M | $108.04M | $105.17M | $105.3M | $95.67M | $87.86M | $96.91M | $47.19M | $45.87M | $36.01M | $44.34M | $35.05M | $27.74M | $20.98M | $17.62M | |
| — | $2.93B | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.9B | $1.8B | $1.61B | $1.33B | $1.92B | $1B | $842.18M | $704.49M | $610.94M | $475.25M | $375.72M | $308.23M | $256.74M | |
| — | $315.23M | $409.48M | $484.21M | $185.77M | $160.97M | -$82.34M | -$43.44M | -$100.46M | -$123.52M | -$14.7M | -$803.43M | -$110.7M | -$92.89M | -$156.01M | -$110.22M | -$33.89M | $544K | $16.43M | $39.76M | |
| — | — | 12.71% | 16.97% | 7.68% | 7.68% | -4.46% | -2.33% | -5.9% | -8.28% | -1.12% | -71.94% | -12.44% | -12.4% | -28.44% | -22.01% | -7.68% | 0.14% | 5.06% | 13.41% | |
| — | — | $489.04M | $580.64M | $290.16M | $262.94M | $25.7M | $61.73M | $4.84M | -$27.85M | $73.16M | -$706.52M | -$63.52M | -$47.02M | -$119.99M | -$65.88M | $1.16M | $28.28M | $37.4M | $57.37M | |
| — | $18.08M | $10.9M | $12.67M | $17.34M | $15.97M | $15.34M | $29.31M | $23.46M | $43.66M | $42.71M | $39.5M | $38.24M | $36.64M | $10.45M | $7.64M | $8.41M | $10.82M | $14.09M | $16.39M | |
| — | $78.45M | $74.9M | $74.88M | $58.34M | $18.03M | $10.48M | $16.61M | $22.75M | $22.83M | $14.85M | $7.49M | $4.5M | $5.94M | $3.08M | $2.58M | $2.93M | $4.11M | $5.09M | $16.39M | |
| — | -$278K | — | — | — | — | — | -$6000 | -$587K | -$553K | -$1.29M | -$538K | -$817K | -$877K | -$1.15M | -$1.22M | -$2.43M | -$2.99M | -$2.59M | -$2.27M | |
| — | $385.59M | $482.48M | $541.76M | $188.56M | $149.58M | -$75.35M | -$49M | -$94.81M | -$142.71M | -$35.88M | -$831.05M | -$154.72M | -$124.87M | -$176.5M | -$118.28M | -$43.63M | -$21.49M | $566K | $33.42M | |
| — | $116.85M | $133.58M | $114.9M | $20.92M | $8.02M | -$11.27M | -$903.03M | -$70.96M | -$65.49M | $81.17M | -$200.84M | $17.08M | $9.1M | -$150K | -$3.93M | $10.21M | -$227.31M | $1.05M | $2.59M | |
| — | $268.74M | $348.9M | $426.86M | $167.65M | $141.56M | -$64.08M | $854.03M | -$23.85M | -$77.21M | -$117.04M | -$630.21M | -$171.8M | -$133.97M | -$176.35M | -$114.35M | -$53.84M | $205.82M | -$488K | $30.83M | |
| — | — | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% | 45.9% | -1.4% | -5.18% | -8.91% | -56.43% | -19.31% | -17.88% | -32.15% | -22.84% | -12.2% | 54.7% | -0.15% | 10.4% | |
| — | $268.74M | $348.9M | $426.86M | $167.65M | $141.56M | -$64.08M | $854.03M | -$23.85M | -$77.21M | -$117.04M | -$630.21M | -$171.8M | -$133.97M | — | -$114.35M | -$53.84M | $205.82M | -$488K | — | |
| — | $245.35M | $273.78M | $517.3M | $142.72M | $123.26M | -$33.51M | $817.73M | -$8.96M | -$48.39M | -$152.82M | -$638.43M | -$178.23M | -$111.52M | -$171.13M | -$119.44M | -$49.14M | $205.07M | -$661K | $31.8M | |
| USD/shares | — | — | $1.82 | $2.25 | $0.89 | $0.76 | -$0.35 | $4.72 | -$0.13 | -$0.44 | -$0.67 | -$3.80 | -$1.07 | -$0.92 | — | -$0.95 | -$0.48 | $2.00 | $0.00 | $0.31 |
| USD/shares | — | — | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 | $4.50 | -$0.13 | -$0.44 | -$0.67 | -$3.81 | -$1.07 | -$0.92 | — | -$0.95 | -$0.48 | $1.73 | $0.00 | $0.29 |
| shares | — | — | 191.79M | 190.03M | 187.83M | 185.27M | 182.85M | 180.8M | 179.04M | 177.06M | 174.43M | 165.99M | 160.03M | 146.35M | 137.76M | 120.27M | 112.12M | 103.09M | 100.27M | 98.98M |
| shares | — | — | 197.39M | 196.71M | 191.6M | 188.96M | 182.85M | 191.68M | 179.04M | 177.27M | 174.43M | 166.22M | 160.03M | 146.35M | 137.76M | 120.27M | 112.12M | 125.67M | 100.27M | 103.57M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2022: $50M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
43.40×
Biotechnology median 7.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $3,221,253,000 | $2,853,915,000 | $2,419,226,000 | $2,096,039,000 |
By Geography (USD)
| Component | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|
| United States | $912,375,000 | $778,440,000 | $696,793,000 | $588,243,000 |
| Europe | $518,465,000 | $509,188,000 | $436,434,000 | $398,814,000 |
| Rest of World | $223,753,000 | $197,628,000 | $172,939,000 | $144,619,000 |
| Latin America | $205,862,000 | $218,792,000 | $185,046,000 | $181,970,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $3,167,759,000 | $2,809,445,000 | $2,372,538,000 | $2,042,025,000 | $1,783,498,000 | $1,805,861,000 | $1,661,043,000 | $1,470,356,000 |
| VOXZOGO | $926,923,000 | $735,092,000 | $469,881,000 | $169,128,000 | $5,855,000 | — | — | — |
| VIMIZIM | $792,051,000 | $739,784,000 | $701,053,000 | $663,739,000 | $623,145,000 | — | — | — |
| NAGLAZYME | $485,400,000 | $479,584,000 | $420,292,000 | $443,794,000 | $380,449,000 | — | — | — |
| PALYNZIQ | $433,310,000 | $355,047,000 | $303,919,000 | $255,032,000 | $237,474,000 | — | — | — |
| ALDURAZYME | $208,508,000 | $183,887,000 | $131,248,000 | $128,422,000 | $122,765,000 | — | — | — |
| BRINEURA | $186,397,000 | $169,083,000 | $161,889,000 | $154,333,000 | $128,034,000 | — | — | — |
| KUVAN | $99,530,000 | $120,902,000 | $180,767,000 | $227,577,000 | $285,776,000 | — | — | — |
| Royalty and Other | $53,494,000 | $44,470,000 | $46,688,000 | $54,014,000 | $62,777,000 | $54,594,000 | $43,005,000 | $20,856,000 |
| ROCTAVIAN | $35,640,000 | $26,066,000 | $3,489,000 | $0 | $0 | — | — | — |
| Enzyme Product | — | — | $1,718,401,000 | $1,645,320,000 | $1,491,867,000 | — | — | — |
Key facts
CIK
1048477
CUSIP
09061G101
13F (30d)
37 filings
15 filers
Visit website
Investor relations